Is the GLP-1 era forcing a marketing reset for FMCG brands?

India’s food and FMCG companies have a new variable to contend with, and it’s not coming from within their industry. Last month, the Drug Controller General of India stepped up regulatory surveillance on GLP-1 drugs, issuing a comprehensive advisory to curb misleading promotions and unauthorised use. The regulator made it clear that these drugs can only be prescribed by qualified specialists such as endocrinologists, internal medicine experts, and cardiologists. 

In recent weeks, authorities audited 49 online pharmacies, wholesalers, retailers, and weight-loss clinics, flagging violations related to unauthorised sales and improper prescription practices, and warning of license cancellations, fines, and legal action for non-compliance. This comes days after the patent for semaglutide, the active ingredient behind drugs like Ozempic and Wegovy, expired in India, triggering a wave of lower-cost generics and sharply bringing down monthly treatment costs. 

While the regulatory focus is firmly on health safeguards, the ripple effects of GLP-1 adoption are already being felt far beyond medicine. Globally, what began as a breakthrough in diabetes treatment has evolved into a broader behavioural shift. For context, GLP-1 drugs (glucagon-like peptide-1 receptor agonists) are designed to regulate blood sugar by stimulating insulin release and suppressing excess glucagon, while also slowing gastric emptying, making people feel fuller for longer and reducing appetite.

In markets like the US, their rapid uptake has started to reshape consumption patterns, cutting down demand for high-frequency indulgence categories such as snacks and desserts, and accelerating a shift towards more nutrient-dense, functional foods. That global conversation is now finding resonance in India. Early adoption may be concentrated among affluent, urban consumers, but the combination of falling prices and increasing awareness is expanding their reach. For the food industry, the implications are becoming harder to ignore.

“The marketing language is already shifting from ‘tastes great’ to ‘every bite counts,’” said Dr Sanjay Arora, Managing Partner, Shells Advertising Inc. “Product discovery is moving online, with GLP-1 users significantly more likely to shop via apps, and the entire wellness category is getting a lift.” He added that the India story has changed almost overnight following the semaglutide patent expiry, with prices falling sharply and over 40 pharma players entering the market. 

For FMCG marketers, whose playbooks are built on driving frequency, impulse, and repeat consumption, this raises fundamental questions about future demand patterns and category growth. The industry is being forced to rethink how food is positioned, discovered, and consumed.

The early signals of that shift are already visible. As Sraman Majumdar, Executive Creative Director, Brave New World points out, GLP-1 adoption in India is currently concentrated among affluent, urban consumers — “people in big cities with relatively higher incomes, the same cohort that experiments with premium snacks, discovers new dessert spots, and ends up shaping a lot of consumption trends.” While still a small segment, their outsized influence on premium food categories makes them a critical group to watch.

The first behavioural shift, Majumdar suggests, may not be what people eat, but why they eat. “When you get on something that drops the craving, the first thing to take a hit is eating to fill your time.” In its place, consumption could become more intentional, centred around smaller portions, “real food,” and occasional indulgence driven by experience rather than impulse.

“Consumption is gradually moving from being frequent and impulse-driven to being more deliberate. People may not stop eating snacks or indulgent foods, but they will start choosing them more carefully and in smaller quantities,” said Rajesh Radhakrishnan, Co-Founder and CMO at Vritti iMedia & Mindwave Media. “The conversation is shifting from ‘more’ to ‘better’, whether that’s better ingredients, better nutrition, or a more fulfilling experience.”

“As this behaviour evolves, brands will also need to rethink discovery and innovation, moving beyond traditional retail to more health-led ecosystems, while building products that combine taste with function, such as high-protein or low-sugar offerings,” he added.

Globally, brands are already responding to this shift—not by retreating, but by repositioning. As Arora added, “GLP-1 users don’t stop buying food, they buy better food, and they’re willing to pay more for it,” with a significant proportion willing to pay a premium for products with added health benefits. 

This has prompted a strategic pivot among large food companies. Nestlé, for instance, has launched its first new brand in nearly three decades tailored specifically for GLP-1 users, focussing on high-protein, nutrient-dense, portion-controlled offerings. Meanwhile, General Mills has begun targeting this cohort through digital media, seeing a reported 20% lift in purchases of its Fiber One bars among GLP-1 consumers.

For many impulse-driven categories, that is likely to be a stress test. As Majumdar notes, brands that rely purely on habitual or filler consumption may struggle to stay relevant, while those offering genuine nourishment or meaningful indulgence are better positioned to sustain demand, regardless of the impact of GLP-1.

Industry experts say this is less a short-term disruption and more a structural shift in consumer behaviour. 

According to Dhruv Tomar, Founder of M-Lense Research, the rise of GLP-1 drugs is accelerating an already emerging trend towards conscious consumption. “Intentional eating, where quality, nutrition, and functional value matter more than quantity, is gradually replacing frequent snacking and impulsive consumption,” he explains.

For food marketers, this signals a clear pivot. Traditional strategies built on indulgence and repeat consumption may need to give way to a more value-driven approach. “Marketing can no longer rely purely on frequency,” Tomar noted, adding that brands will need to focus on nutritional value, ingredient transparency, and functional benefits, alongside offering smaller, more efficient portion formats.

As consumers become more deliberate in their choices, the role of communication and trust becomes sharper. Brands that can clearly articulate quality, safety, and purpose are likely to stand out in a market where consumers are taking more time to evaluate what they eat.

The government’s recent actions, including inspections across online and offline supply chains and strict action against misleading promotions, highlight concerns around unsupervised use and potential side effects if these drugs are consumed without medical guidance. 

For now, GLP-1 may still be an emerging trend in India, but the mindset it represents is already taking hold. As Tomar puts it, “even if GLP-1 is a long-term trend here, brands should begin preparing for its mindset now.” That means moving away from volume-led growth towards building trust, aligning with health-conscious consumers, and rethinking product portfolios for a future where appetite itself may no longer be the primary driver of demand.